Category: Laparoscopic/ Robotic: Other

MP30-7 - Open versus robot assisted radical cystectomy and orthotopic neobladder: Mid-term single center propensity score matched analysis of perioperative and oncologic outcomes.

Sun, Sep 23
2:00 PM - 4:00 PM

Introduction & Objective :

Oncologic equivalence open radical cystectomy (ORC) and robot-assisted radical cystectomy (RARC) remains a debatable issue and prospective randomized trials comparing these two approaches are hard to perform. In this study We compared oncologic outcomes of propensity score matched cohorts of patients treated with either ORC and orthotopic neobladder (ON) or RARC and intracorporeal ON. 


Methods :

The institutional review board approved prospective bladder cancerdatabase was queried for  “cystectomy with curative intent” and “neobladder”. A 1:1 PSM analysis was used to minimize the potential biases of a retrospective analysis of data. Kaplan-Meier method was used to compare the oncologic outcomes of the PSM cohorts. Survival rates were computed at 2, 3 and 4 years after surgery and the log rank test was applied to assess statistical significance between the two PSM groups<./p>


Results :

Overall 363 patients with a minimum follow-up length of 2 years were included, 299 of which treated with ORC and 64 with RARC. A comparison of oncologic outcomes between ORC and RARC was performed.  Patients treated with open surgery were less frequently male (p=0.08), with higher pT stage (p=0.008), higher incidence of non-urothelial histologies (0.05) and lesser adoption of neoadjuvant chemotherapy (<0.001).
After applying the PSM, 64 RARC patients were matched with 46 ORC cases. The two groups did not differ for all clinical and pathologic variables included in the analysis (all p ≥0.22). All data are summarized in table 1. At Kaplan-Meier analysis RARC and ORC cohorts displayed comparable disease free survival (log rank p= 0.894; Figure 1a), cancer specific survival (log rank p=0.8; Figure 1b) and overall survival rates (log rank p= 0.97; Figure 1c).


Conclusions :

RARC with intracorporeal neobladder provides an optimal control of soft tissue surgical margins and of LN yield. Preliminary oncologic outcomes suggest that patients treated with RARC and intracorporeal neobladder display comparable disease free survival of patients treated with open surgery.

Giuseppe Simone

Consultant
“Regina Elena” National Cancer Institute, Dept. of Urology
Roma, Lazio, Italy

Gabriele Tuderti

Fellow
"Regina Elena" National Cancer Institute, Dept. of Urology
Roma, Lazio, Italy

Leonardo Misuraca

Fellow
"Regina Elena" National Cancer Institute, Dept. of Urology
Rome, Lazio, Italy

Mariaconsiglia Ferriero

MD, PhD
"Regina Elena" National Cancer Institute, Dept. of Urology
Rome, Lazio, Italy

Umberto Anceschi

"Regina Elena" National Cancer Institute, Dept.of Urology
Rome, Lazio, Italy

Salvatore Guaglianone

"Regina Elena" National Cancer Institute, Dept. of Urology
Roma, Lazio, Italy

Francesco Minisola

"Regina Elena" National Cancer Institute, Dept. of Urology
Roma, Lazio, Italy

Michele Gallucci

Roma, Lazio, Italy